Infixion Bioscience

Infixion Bioscience is a private, pre-clinical biotech founded in 2021, focusing exclusively on Neurofibromatosis Type 1 (NF1). The company is developing a novel therapeutic approach designed to restore functional neurofibromin protein, targeting the genetic root cause of the disease rather than just symptoms. Operating in the rare disease space with significant market incentives, Infixion appears to be in the early stages of research and development, supported by foundational grants and engagement with the NF community. Its success hinges on validating its unique mechanism and advancing a candidate into clinical trials.

Platform focused on enhancing the body's ability to produce and maintain functional neurofibromin protein to treat the root cause of NF1.

Competition includes companies like AstraZeneca (selumetinib, approved) and others developing MEK inhibitors for tumor manifestations. Infixion differentiates by targeting the upstream root cause (neurofibromin deficiency), which, if successful, could offer broader therapeutic benefit beyond tumor suppression.